Phase 1b/2a in SLE With Budoputug
NCT06570434 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL
Last updated 2024-10-16
Summary
The purpose of the study is to determine the safety, tolerability, and pharmacokinetics of budoprutug in participants with SLE
Conditions
- Systemic Lupus Erythematosus
- SLE
- B Cells
Interventions
- DRUG
-
budoprutug
monoclonal antibody
Sponsors & Collaborators
-
Tenet Medicines
lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-31
- Primary Completion
- 2026-12-31
- Completion
- 2027-04-30
- FDA Drug
- Yes
More Related Trials
-
Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study
NCT00271934 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
NCT02265744 ·Status: COMPLETED ·Phase: PHASE2
-
Inaticabtagene Autoleucel Injection in the Treatment of Refractory Systemic Lupus Erythematosus-related Immune Thrombocytopenia
NCT06826430 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis
NCT04924296 ·Status: UNKNOWN ·Phase: PHASE2
-
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
NCT06032923 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
NCT06434363 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus
NCT01702740 ·Status: COMPLETED ·Phase: PHASE1
-
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
NCT05688696 ·Status: RECRUITING ·Phase: PHASE2
-
Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
NCT06310811 ·Status: SUSPENDED ·Phase: NA
-
Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease
NCT00624351 ·Status: COMPLETED ·Phase: PHASE2
-
Obe-cel in Adolescent [Applicable in UK Only] and Adult Severe, Refractory Systemic Lupus Erythematosus
NCT06333483 ·Status: RECRUITING ·Phase: PHASE1
-
Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus
NCT01764594 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus
NCT01262365 ·Status: COMPLETED ·Phase: PHASE3
-
Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)
NCT00094380 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus
NCT00017641 ·Status: UNKNOWN ·Phase: PHASE1
-
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
NCT01405196 ·Status: COMPLETED ·Phase: PHASE2
-
Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients
NCT02307643 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)
NCT01261793 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
NCT07340463 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants
NCT05278663 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)
NCT03724916 ·Status: COMPLETED ·Phase: PHASE1
-
An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184
NCT01777256 ·Status: TERMINATED ·Phase: PHASE2
-
Safety of Administering Isoniazid to SLE Patients to Prevent TB
NCT06618573 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE
NCT01702038 ·Status: WITHDRAWN ·Phase: PHASE2